Literature DB >> 15967468

Recovery and prognosticators of paralysis in West Nile virus infection.

Nancy Jingyang Cao1, Chakpapani Ranganathan, William J Kupsky, Jun Li.   

Abstract

Previous studies have demonstrated that lesions of the anterior horn motor neurons are the primary pathology in patients with paralysis due to West Nile virus (WNV) infection. To characterize recovery and identify prognostic factors for the recovery of paralysis, we investigated 11 patients with electrophysiology testing and muscle biopsy, and one with autopsy. We found that limb weakness was markedly asymmetric and differed between upper and lower extremities, suggesting focal or segmental involvement of the spinal cord anterior horn. This was supported by segmental depletion of spinal motor neurons at autopsy. Clinical recovery was variable during a 21-month follow-up period. To explain variability, we performed motor unit number estimation (MUNE) in six patients. MUNE values and strength were correlated in tested muscles. We also detected motor nerve terminal damages in muscle biopsies, suggesting another possible mechanism for transient weakness and variable recovery. We conclude that the type of pathological lesions may vary in paralytic WNV infection, and different degrees or combinations of motor neuron loss and motor nerve terminal changes may account for the observed degrees of weakness and recovery.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15967468     DOI: 10.1016/j.jns.2005.05.007

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  14 in total

1.  West Nile virus-associated acute flaccid paralysis.

Authors:  Ashely Alker
Journal:  BMJ Case Rep       Date:  2015-05-02

Review 2.  West Nile virus meningoencephalitis.

Authors:  Roberta L Debiasi; Kenneth L Tyler
Journal:  Nat Clin Pract Neurol       Date:  2006-05

Review 3.  Neurological approaches for investigating West Nile virus disease and its treatment in rodents.

Authors:  John D Morrey; Venkatraman Siddharthan; Hong Wang
Journal:  Antiviral Res       Date:  2013-09-19       Impact factor: 5.970

4.  Persistence of West Nile virus in the central nervous system and periphery of mice.

Authors:  Kim K Appler; Ashley N Brown; Barbara S Stewart; Melissa J Behr; Valerie L Demarest; Susan J Wong; Kristen A Bernard
Journal:  PLoS One       Date:  2010-05-14       Impact factor: 3.240

5.  Southern California neuroinvasive West Nile virus case series.

Authors:  Chirag B Patel; Bhavesh V Trikamji; Glenn E Mathisen; Shrikant K Mishra
Journal:  Neurol Sci       Date:  2017-11-08       Impact factor: 3.307

6.  West Nile virus-induced acute flaccid paralysis is prevented by monoclonal antibody treatment when administered after infection of spinal cord neurons.

Authors:  John D Morrey; Venkatraman Siddharthan; Hong Wang; Jeffery O Hall; Ramona T Skirpstunas; Aaron L Olsen; Jeffrey L Nordstrom; Scott Koenig; Syd Johnson; Michael S Diamond
Journal:  J Neurovirol       Date:  2008-04       Impact factor: 2.643

7.  Persistent West Nile virus associated with a neurological sequela in hamsters identified by motor unit number estimation.

Authors:  Venkatraman Siddharthan; Hong Wang; Neil E Motter; Jeffery O Hall; Robert D Skinner; Ramona T Skirpstunas; John D Morrey
Journal:  J Virol       Date:  2009-02-18       Impact factor: 5.103

8.  Disrupted glutamate transporter expression in the spinal cord with acute flaccid paralysis caused by West Nile virus infection.

Authors:  Pennelope K Blakely; Bette K Kleinschmidt-DeMasters; Kenneth L Tyler; David N Irani
Journal:  J Neuropathol Exp Neurol       Date:  2009-10       Impact factor: 3.685

9.  Prognosis of West Nile virus associated acute flaccid paralysis: a case series.

Authors:  Jennie Johnstone; Steven E Hanna; Lindsay E Nicolle; Michael A Drebot; Binod Neupane; James B Mahony; Mark B Loeb
Journal:  J Med Case Rep       Date:  2011-08-19

Review 10.  A review of vaccine approaches for West Nile virus.

Authors:  Arun V Iyer; Konstantin G Kousoulas
Journal:  Int J Environ Res Public Health       Date:  2013-09-10       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.